https://www.selleckchem.com/pr....oducts/ldc203974-imt
nowledge, we report the first clinical comparison of the 2 grafts in our case series with thrombophilic risk factors. Allogeneic stem cell transplantation from haploidentical donor using an unmanipulated graft and post-transplantation cyclophosphamide (PT-Cy) is growing. Haploidentical transplantation with PT-Cy showed a major activity in Hodgkin lymphoma (HL), reducing the relapse incidence. The most important predictive factor of survival and toxicity was disease status before transplantation, which was better in patients with
Like
Comment
Share
